At the Bedside

  • Immediate assessment
  • ABCs first: assess respiratory rate, oxygen saturation, ETCO₂ if available, mental status, airway protection.
  • Classic toxidrome: CNS depression + respiratory depression + miosis. Miosis may be absent with hypoxia, co-ingestions, meperidine, tramadol, or severe poisoning.
  • Look for trauma, aspiration, pulmonary edema, hypoglycemia, needle marks, fentanyl patches, clonidine co-ingestion.
  • Initial ED actions
  • High-flow O₂; assist ventilation with BVM if bradypneic/apneic.
  • Place patient on cardiac monitor, pulse ox, and ideally capnography.
  • Check POC glucose early in all altered patients.
  • IV access; consider IO if unstable and IV delayed.
  • Naloxone strategy
  • Goal: restore adequate ventilation, not necessarily normal mentation.
  • In opioid-dependent patients, start low and titrate to avoid severe withdrawal, agitation, vomiting, aspiration.
  • In apnea or near-arrest, give larger doses immediately.
  • Re-dose as needed; fentanyl analogs, methadone, extended-release opioids, and body stuffing/packing may require repeated doses or infusion.
  • Diagnostic workup
  • Often clinical diagnosis.
  • POC glucose.
  • ECG if methadone, loperamide, co-ingestion, syncope, or unknown overdose.
  • Acetaminophen/salicylate levels and ethanol level are reasonable in intentional/unknown ingestions.
  • VBG/ABG if severe hypoventilation, persistent AMS, or respiratory failure.
  • CXR if hypoxia, aspiration concern, pulmonary edema.
  • Urine drug screen has limited ED utility; fentanyl often not detected on standard screens.
  • Complications
  • Aspiration pneumonitis/pneumonia.
  • Noncardiogenic pulmonary edema after overdose or naloxone.
  • Rhabdomyolysis from prolonged down time.
  • Withdrawal after naloxone: agitation, vomiting, diarrhea, tachycardia, hypertension.
  • Disposition
  • Observe until awake, breathing normally, and no recurrent sedation after naloxone.
  • Short-acting opioid reversed with naloxone: often observe 2–4 hours after last naloxone if clinically stable.
  • Admit/extended observation if long-acting opioid, methadone, buprenorphine, recurrent naloxone needs, naloxone infusion, hypoxia, aspiration, pulmonary edema, significant co-ingestion, suicidal intent, pregnancy, unreliable follow-up.
  • Offer harm reduction: take-home naloxone, fentanyl test strips where available, buprenorphine initiation if opioid use disorder and appropriate.
A Classic Presentation
A 28-year-old man is brought in after being found unresponsive in a bathroom. He has RR 6, SpO₂ 82%, pinpoint pupils, and fresh injection marks. Glucose is 104. He receives BVM ventilation and 0.4 mg IV naloxone with improved RR to 14 and oxygenation. After 90 minutes he becomes somnolent again, requiring repeat naloxone; because recurrent toxicity suggests fentanyl/longer-acting exposure, a naloxone infusion is started and he is admitted.

Study Directive

  • Practice a 60-second opioid overdose script: airway, glucose, BVM, naloxone titration, reassessment.
  • Memorize naloxone titration: 0.04 mg IV for dependent/non-apneic patients; 0.4–2 mg for apnea/severe depression; infusion = 2/3 wake-up dose per hour.
  • Review criteria for safe discharge after naloxone and list 5 reasons for admission.
  • Simulate counseling: prescribe take-home naloxone and offer buprenorphine initiation for OUD.

Recent Literature